Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
Authors
Wen C, Zheng Z, Shao T, Liu L, Xie Z, Le Chatelier E, He Z, Zhong W, Fan Y, Zhang L, Li H, Wu C, Hu C, Xu Q, Zhou J, Cai S, Wang D, Huang Y, Breban M, Qin N, Ehrlich SD
Journal
Genome biology
Year
2017
Keywords:
Ankylosing spondylitis, Biomarkers, Human gut microbiome, Pathogenesis
BACKGROUND: The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing spondylitis is an inflammatory autoimmune disease and evidence showed that ankylosing spondylitis may be a microbiome-driven disease. RESULTS: To investigate the relationship between the gut microbiome and ankylosing spondylitis, a quantitative metagenomics study based on deep shotgun sequencing was performed, using gut microbial DNA from 211 Chinese individuals. A total of 23,709 genes and 12 metagenomic species were shown to be differentially abundant between ankylosing spondylitis patients and healthy controls. Patients were characterized by a form of gut microbial dysbiosis that is more prominent than previously reported cases with inflammatory bowel disease. Specifically, the ankylosing spondylitis patients demonstrated increases in the abundance of Prevotella melaninogenica, Prevotella copri, and Prevotella sp. C561 and decreases in Bacteroides spp. It is noteworthy that the Bifidobacterium genus, which is commonly used in probiotics, accumulated in the ankylosing spondylitis patients. Diagnostic algorithms were established using a subset of these gut microbial biomarkers. CONCLUSIONS: Alterations of the gut microbiome are associated with development of ankylosing spondylitis. Our data suggest biomarkers identified in this study might participate in the pathogenesis or development process of ankylosing spondylitis, providing new leads for the development of new diagnostic tools and potential treatments.
Experiment 1
Reviewed Marked as Reviewed by Chloe on 2023-4-3
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Ankylosing spondylitis Ankylosing Spondylarthritides,Ankylosing Spondylarthritis,ankylosing spondylitis,Ankylosing Spondyloarthritides,Ankylosing Spondyloarthritis,BECHTEREW DIS,Bechterew Disease,Bechterew's Disease,BECHTEREWS DIS,Bechterews Disease,Bekhterev syndrome,Bekhterev's disease,MARIE STRUEMPELL DIS,Marie Struempell Disease,Marie-Struempell Disease,Marie-Strumpell disease,Rheumatoid Spondylitis,Spondylarthritides, Ankylosing,Spondylarthritis Ankylopoietica,Spondylarthritis, Ankylosing,Spondylitis, Ankylosing,Spondylitis, Rheumatoid,Spondyloarthritides, Ankylosing,Spondyloarthritis, Ankylosing,Ankylosing spondylitis
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy controls
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Ankylosing spondylitis patients
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Ankylosing spondylitis confirmed by calculating the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
- Group 0 sample size Number of subjects in the control (unexposed) group
- 114
- Group 1 sample size Number of subjects in the case (exposed) group
- 97
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 4 weeks
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.001
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- decreased
- Richness Number of species
- decreased
Signature 1
Reviewed Marked as Reviewed by Chloe on 2023-4-3
Curated date: 2023/03/15
Curator: Ufuoma Ejite
Revision editor(s): Ufuoma Ejite, Chloe, Aiyshaaaa, Atrayees
Source: Table S4
Description: Differences of phylogenetic abundance between AS patients and healthy controls
Abundance in Group 1: increased abundance in Ankylosing spondylitis patients
Revision editor(s): Ufuoma Ejite, Chloe, Aiyshaaaa, Atrayees
Signature 2
Reviewed Marked as Reviewed by Chloe on 2023-4-3
Source: Table S4
Description: Differences of phylogenetic abundance between AS patients and healthy controls
Abundance in Group 1: decreased abundance in Ankylosing spondylitis patients
Revision editor(s): Ufuoma Ejite, Chloe, Aiyshaaaa
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_638&oldid=106830"